HK1209133A1 - Process for reducing antibody aggregate levels and antibodies produced thereby - Google Patents
Process for reducing antibody aggregate levels and antibodies produced therebyInfo
- Publication number
- HK1209133A1 HK1209133A1 HK15109727.4A HK15109727A HK1209133A1 HK 1209133 A1 HK1209133 A1 HK 1209133A1 HK 15109727 A HK15109727 A HK 15109727A HK 1209133 A1 HK1209133 A1 HK 1209133A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies produced
- aggregate levels
- reducing antibody
- antibody aggregate
- reducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261594671P | 2012-02-03 | 2012-02-03 | |
PCT/EP2013/052078 WO2013113898A1 (en) | 2012-02-03 | 2013-02-01 | Process for reducing antibody aggregate levels and antibodies produced thereby |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209133A1 true HK1209133A1 (en) | 2016-03-24 |
Family
ID=47678781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15109727.4A HK1209133A1 (en) | 2012-02-03 | 2015-10-06 | Process for reducing antibody aggregate levels and antibodies produced thereby |
Country Status (7)
Country | Link |
---|---|
US (1) | US20150005475A1 (de) |
EP (1) | EP2855522A1 (de) |
JP (1) | JP2015510397A (de) |
AU (1) | AU2013214172A1 (de) |
CA (1) | CA2863564A1 (de) |
HK (1) | HK1209133A1 (de) |
WO (1) | WO2013113898A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2895226T3 (es) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
BR112014007035B1 (pt) | 2011-09-23 | 2021-05-04 | Oncomed Pharmaceuticals, Inc | anticorpos biespecíficos que se ligam a vegf/dll4, composição farmacêutica e célula procariótica, fúngica ou de levedura que compreende os mesmos, moléculas de polinucleotídeo, vetor, usos terapêuticos e método para a produção de um anticorpo |
DK3212233T3 (da) | 2014-10-31 | 2020-07-27 | Oncomed Pharm Inc | Kombinationsterapi til behandling af sygdom |
AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
US10310687B2 (en) * | 2016-12-14 | 2019-06-04 | Cypress Semiconductor Corporation | Multi-phase self-capacitance scanning of sensors arrays |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO2010032060A1 (en) * | 2008-09-19 | 2010-03-25 | Medimmune Llc | Antibodies directed to dll4 and uses thereof |
-
2013
- 2013-02-01 US US14/375,244 patent/US20150005475A1/en not_active Abandoned
- 2013-02-01 AU AU2013214172A patent/AU2013214172A1/en not_active Abandoned
- 2013-02-01 EP EP13703012.8A patent/EP2855522A1/de not_active Withdrawn
- 2013-02-01 JP JP2014555230A patent/JP2015510397A/ja active Pending
- 2013-02-01 WO PCT/EP2013/052078 patent/WO2013113898A1/en active Application Filing
- 2013-02-01 CA CA2863564A patent/CA2863564A1/en not_active Abandoned
-
2015
- 2015-10-06 HK HK15109727.4A patent/HK1209133A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2855522A1 (de) | 2015-04-08 |
CA2863564A1 (en) | 2013-08-08 |
WO2013113898A1 (en) | 2013-08-08 |
US20150005475A1 (en) | 2015-01-01 |
AU2013214172A1 (en) | 2014-08-14 |
JP2015510397A (ja) | 2015-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100034I1 (hu) | ANGPTL3-ellenes antitestek és alkalmazásaik | |
IL288203A (en) | Meditops and Meditop binding antibodies and their use | |
HK1256304A1 (zh) | 用於生成單克隆抗體的方法和試劑 | |
HK1210620A1 (en) | Multi-specific monoclonal antibodies | |
ZA201400768B (en) | Interleukin-31 monoclonal antibody | |
IL232399A0 (en) | Anti-2fgfr antibodies and their use | |
EP2742067A4 (de) | Monoklonale fzd10-antikörper und verfahren zu ihrer verwendung | |
EP2746394A4 (de) | Antikörper und antikörper enthaltende zusammensetzung | |
HK1199842A1 (en) | Anti-siglec-15 antibodies and uses thereof -15 | |
EP2861623A4 (de) | Neuartige clec14a-spezifische antikörper und verwendungen davon | |
EP2915819A4 (de) | Antikörper- und antikörperzusammensetzungsherstellungsverfahren | |
SG11201400405TA (en) | Caninised antibodies and method for the production of same | |
HK1209133A1 (en) | Process for reducing antibody aggregate levels and antibodies produced thereby | |
HRP20150468T1 (hr) | Protutijela koja se vežu na tgf-alfa i epiregulin |